Phibro Animal Health Stock Up 152.3% in a Year: What's Driving It?

Core Insights - Phibro Animal Health (PAHC) shares have increased by 152.3% over the past year, significantly outperforming the industry's decline of 22.3% and the S&P 500's gain of 16.6% [1][9] Company Performance - The company currently holds a Zacks Rank 1 (Strong Buy), benefiting from a robust animal health portfolio and the integration of Zoetis' MFA business, which has enhanced its product offerings [2] - In the second quarter of fiscal 2026, MFA revenues grew by 34%, driven by strong performance in nutritional specialties and vaccines, with the new MFA business contributing $94.1 million in sales [5] - The vaccine segment saw a 13% year-over-year increase in net sales, primarily due to growth in poultry products in Latin America and higher international demand [7][9] Product and Market Expansion - Phibro markets around 800 product lines across approximately 90 countries, focusing on food and companion animals, and is investing in the companion animal sector [3] - The MFA product franchise, including Stafac/V-Max/Eskalin, is approved in over 30 countries, and the integration of Zoetis' MFA business has added more than 37 established product lines [4] - The company's global footprint includes key high-growth regions such as Southeast Asia, Mexico, Turkey, and Canada, with net sales in Europe, the Middle East, and Africa increasing by 37.4% year over year [6] Financial Estimates - The Zacks Consensus Estimate projects a 45% increase in earnings per share (EPS) for fiscal 2026, reaching $3.03, and an 8.2% increase for fiscal 2027, reaching $3.28 [12] - Revenues for fiscal 2026 are expected to grow by 14.5% to $1.48 billion, with fiscal 2027 revenues projected to reach $1.54 billion, indicating a 3.5% increase [12] Financial Health - The company has solid liquidity, exiting the quarter with cash and short-term investments totaling $74.5 million and short-term payable debt of $21 million [10]